MetaCap

Aura Biosciences Inc. (AURA)

NASDAQ: AURAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

6.87-0.11 (-1.58%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AURA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$714.99M
EPS (TTM)
-$1.59
52-week range
4.73 – 9.54
Day range
6.51 – 6.97
Volume / Avg
791.13K / 847.22K
Beta
—

52-week range

$4.73$9.54

AURA stock today

Aura Biosciences (AURA) closed at $6.87 on Nov 20, down 1.58% (-$0.11), versus the S&P 500's 3.70% decline. Shares are 27.9% below their 52-week high of $9.54, set on May 5, 2026 and 45.2% above the 52-week low of $4.73, in the middle of the past year's range. AURA is up 26.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 26.3%.

Aura Biosciences has posted a net loss over the last twelve months (EPS of -$1.59), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Aura Biosciences

Company profile

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Ms. Natalie C. Holles
Headquarters
Boston, MA
Employees
113
IPO year
2021

Financial highlights

Full financials

Aura Biosciences reported a net loss of $106.2 million, compared with a loss of $86.9 million a year earlier. Diluted earnings per share came in at -$1.76.

Aura Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-106.19M$-86.92M$-76.41M$-58.76M$-35.25M
EPS (diluted)$-1.76$-1.75$-1.93$-1.96$-8.95

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$16.60+141.63%

  • Strong buy 1
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $23.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.29 vs $-0.31
Surprise
+6.45%

AURA news

All AURA news

Aura Biosciences peers

Health Care sector
AURA peer companies
CompanyPrice% ChgMarket capCompare
GLUEMonte Rosa Therapeutics Inc.8.64-3.03%$738.29Mvs AURA
SLDBSolid Biosciences Inc.6.25-2.95%$697.57Mvs AURA
ATTOAttovia Therapeutics Inc.15.10-3.08%$690.26Mvs AURA
MGTXMeiraGTx Holdings plc7.98-1.97%$779.89Mvs AURA
PRMEPrime Medicine Inc.3.55-7.55%$791.62Mvs AURA
BBTXBambusa Therapeutics Inc.16.00+2.89%$815.08Mvs AURA
ODTXOdyssey Therapeutics Inc.16.96-7.52%$815.23Mvs AURA
IAMIambic Therapeutics Inc.13.11-8.06%$621.42Mvs AURA

Indexes, lists and sector

Aura Biosciences stock FAQ

What is Aura Biosciences's stock price today?

AURA last traded at $6.87 as of Nov 20, 4:00 PM EST, down 1.58% on the day. Prices are delayed at least 15 minutes.

Who is Aura Biosciences's CEO?

Ms. Natalie C. Holles is the chief executive officer of Aura Biosciences Inc., which has about 113 employees.

What is the AURA 52-week high?

The 52-week high for AURA is $9.54 and the 52-week low is $4.73. The stock is currently 27.9% below its high.

Compare AURA